Article Per Year (5 Year)
p-Index From 2021 - 2026
1.978
P-Index
This Author published in this journals
All Journal Indonesian Journal of Pharmaceutical Science and Technology Jurnal Kesehatan Masyarakat (JKM) CENDEKIA UTAMA JMM (Jurnal Masyarakat Mandiri) Jurnal Kreativitas PKM PengabdianMu: Jurnal Ilmiah Pengabdian kepada Masyarakat Jurnal Penelitian dan Pengkajian Ilmu Pendidikan: e-Saintika Journal of Herbal, Clinical and Pharmaceutical Science (HERCLIPS) Medical Sains : Jurnal Ilmiah Kefarmasian Ahmad Dahlan Medical Journal Eduvest - Journal of Universal Studies Borneo Journal of Pharmacy Medical Sains : Jurnal Ilmiah Kefarmasian
Amaliyah Dina Anggraeni
Universitas Muhammadiyah Malang
Aerospace Engineering Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Economics, Econometrics & Finance Education Environmental Science Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Mathematics Medicine & Pharmacology Neuroscience Nursing Physics Public Health Social Sciences Other

Published : 12 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 12 Documents
Search

 1   2 
A Literature Review on the Antihyperglycemic Effect of Nanoencapsulated Etlingera eatior Extract in Type 2 Diabetes Mellitus Salsabiella, Elok; Anggraeni, Amaliyah Dina; Prastiyo, Muhammad Dodik
Ahmad Dahlan Medical Journal Vol. 6 No. 1 (2025): May 2025
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/admj.v6i1.12966

Abstract

Diabetes mellitus Type 2 (T2DM) is characterized by hyperglycemia due to pancreatic β-cell damage, leading to impaired insulin production. The International Diabetes Federation (IDF) estimates that by 2021, 537 million people worldwide will have T2DM, with projections reaching 783 million people by 2045. In 2023, Indonesia reported a diabetes prevalence of 9.1%, affecting around 25 million people. Nanocarrier-based drug delivery systems show promise in improving diabetes management by enhancing bioavailability and sustaining drug release. This study tested the effectiveness of a nano drug delivery system using nanoencapsulation of Etlingera elatior extract in T2DM therapy. Etlingera elatior contains flavonoids, polyphenols, saponins, and alkaloids, which exhibit significant antihyperglycemic properties. Nanoencapsulation with biodegradable polymers improves stability and controlled release of bioactive compounds. Using a qualitative document study, data sourced from Google Scholar and Publish or Perish with a range of 2015-2024 were analyzed through NVivo 12 Pro software for MacBook Pro. The findings showed that Etlingera elatior effectively lowered blood glucose, improved insulin sensitivity, and protected β-cells, while nanoencapsulation optimized bioavailability. Thus, nanoencapsulation of Etlingera elatior represents a promising innovation for diabetes management, potentially improving glucose control and patient outcomes in Indonesia.
Analysis Of The Relationship Of Covid-19 Symptoms Which Receive Favipiravir And Length Of Treatment In The Inpatition Of Dr. Iskak Tulungagung Inayah, Aghnia Fuadatul; Shabrina Putri, Ghassani; Anggraeni, Amaliyah Dina
Eduvest - Journal of Universal Studies Vol. 4 No. 5 (2024): Journal Eduvest - Journal of Universal Studies
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/eduvest.v4i5.1277

Abstract

Coronavirus disease 2019 or commonly called COVID-19 is an infectious disease caused by SARS-CoV-2. Favipiravir is a broad-spectrum antiviral drug so it has potential antiviral action against SARS-CoV-2 which is an RNA virus. This research aims to find out the relationship between Covid-19 symptoms when receiving favipiravir and the length of treatment of patients hospitalized at RSUD Dr. Iskak Tulungagung. Observational research with descriptive retrospective methods in COVID-19 patients' moderate symptoms with Favipiravir therapy at RSUD dr. Iskak Tungagung period July - September 2021. Data collection using the calculation of the Slovin formula to determine the number of patient samples. Analysis analysis using SPSS by carrying out the Chi-square test. The results of the study were obtained from 146 patients, the pattern of using Favipiravir was given at a dose (2x1600mg) on the first day followed by (2x600mg) on the second day and so on with the most giving range of 1-7 days .
Co-Authors Afifah, Salmahikaru Ahmad Shobrun Jamil Elly Purwanti Haryoto Haryoto Heng Yen Khong Hidajah Rachmawati Inayah, Aghnia Fuadatul Kurnia Putri Utami Lestari, Nadia A. M. Artabah Muchlisin Moh. Mirza Nuryady Moonike Era Wahyuningati Muhammad Dodik Prastiyo Muhammad Priyadi Nia Yuniar Fitriana Putri Nungki Marlian Yuliadarwati Paramitha, Alfina I. Refie Putri Madiyanti Sadatiyah, Sadatiyah Salsabiella, Elok Septia Devi Amalia Shabrina Putri, Ghassani Siti Rofida Solly Aryza Tutut Indria Permana Ulfiatul Jannah Yustika Faradhiba Yustika Savira